Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

BACKGROUND: Osimertinib monotherapy is currently the standard of care as a first-line treatment for patients harboring epidermal growth factor receptor (EGFR) mutations; however, some EGFR-mutated non-small cell lung cancer (NSCLC) patients exhibit primary resistance and an insufficient response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Akihiro, Yamada, Tadaaki, Okuma, Yusuke, Fukuda, Akito, Watanabe, Satoshi, Nishioka, Naoya, Takeda, Takayuki, Chihara, Yusuke, Takemoto, Shinnosuke, Harada, Taishi, Hiranuma, Osamu, Shirai, Yukina, Nishiyama, Akihiro, Yano, Seiji, Goto, Yasuhiro, Shiotsu, Shinsuke, Kunimasa, Kei, Morimoto, Yoshie, Iwasaku, Masahiro, Kaneko, Yoshiko, Uchino, Junji, Kenmotsu, Hirotsugu, Takahashi, Toshiaki, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435385/
https://www.ncbi.nlm.nih.gov/pubmed/34584858
http://dx.doi.org/10.21037/tlcr-21-461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435385/
https://www.ncbi.nlm.nih.gov/pubmed/34584858
http://dx.doi.org/10.21037/tlcr-21-461

Ejemplares similares